CICC Capital has co-joined Global Technology’s Series C round, while 3H Health Investment has led Chamlion’s Series B round. Also, Ubrigene has snapped almost $22 million in an extended C round.
Global Technology bags $58m in Series C round
Global Technology, which develops drive-by-wire systems and hardwares used in autonomous vehicles, has notched 400 million yuan ($58 million) in a Series C round.
Drive-by-wire technology enables the use of electric or electronic components to perform vehicle functions such as brake activation and steer control that have been traditionally done mechanically.
The round saw the participation of notable investors including CICC Capital, Shenzhen Investment Holdings Capital, Tsinghua Research Capital, Guosen H&S, and Xinding Capital, among others, according to a company release on April 22.
Founded in 2016, the firm previously garnered 200 million yuan ($31 million) in a Series B++ round in March 2022, joined by a slew of notable firms including Baidu Venture, Xinding Capital, and Value Capital, Chifortune Venture, Haidao Capital, and Hejia Fund.
Chamlion snaps $34m in Series B funding
Dental 3D printing firm Chamlion Laser Technology has secured 236 million yuan ($34.2m) in a Series B round led by 3H Health Investment.
The round, joined by Vertex Ventures China and Zhencheng Capital, will help the firm in overseas business expansion, according to a release on April 18.
Founded in September 2017, Nanjing-based Chamlion offers one-stop dental 3D printing solutions and hardware, ranging from dental 3D printers, intelligent denture design software, and heat treatment furnaces.
Previously, the firm raised 140 million yuan ($20.3 million) in a Series A round exclusively invested by Zhencheng Capital in July 2022.
Ubrigene nets almost $22m in extended Series C round
Contract development and manufacturing organisation (CDMO) firm Ubrigene has snagged 150 million yuan ($21.7 million) in an extended Series C round.
Guotai Junan Innovation Investment; a fund under Jinan Industrial Development Investment Group; and Jinan Sci-tech Venture Capital, led the round; while FoF Capital Fund re-upped.
The Beijing-based firm intends to use the proceeds on its global expansion plan, according to a release on April 19.
Founded in October 2015, the firm offers a spectrum of CDMO services targeting cell and gene therapies such as plasmids, cell therapy and gene therapy, among others, with manufacturing bases in the city of Suzhou and Jinan.
Previously, it notched “several hundreds of millions” yuan in a Series C round led by CLSA Capital Partners, Sichuan Provincial Investment Group, and Goldstone Investment.